A5101864937- Cancer Genomics and Diagnostics
- Genetic factors in colorectal cancer
- Cancer-related molecular mechanisms research
- Pancreatic and Hepatic Oncology Research
- Epigenetics and DNA Methylation
- Genetic Syndromes and Imprinting
- Blood disorders and treatments
- Nicotinic Acetylcholine Receptors Study
- Circular RNAs in diseases
- Marine Toxins and Detection Methods
- Chronic Lymphocytic Leukemia Research
- Single-cell and spatial transcriptomics
- Bioinformatics and Genomic Networks
- Multiple Myeloma Research and Treatments
- Extracellular vesicles in disease
- Molecular Biology Techniques and Applications
- Gene expression and cancer classification
- Radical Photochemical Reactions
- BRCA gene mutations in cancer
Zhongnan Hospital of Wuhan University
2024
Wuhan University
2024
German Cancer Research Center
2017-2020
Heidelberg University
2017-2020
University Hospital Heidelberg
2017
GlaxoSmithKline (United States)
2012
University of New Orleans
2004
Non-invasive blood-based molecule markers are evaluated as promising biomarkers these days. Here we investigated the potential of cell-free circulating DNA Integrity (cfDI) marker for prediction recurrence during follow-up breast cancer patients within a prospective study cohort. cfDI was determined in plasma 212 individuals, by measuring ALU and LINE1 repetitive elements using quantitative PCR. A significant decrease recurrent observed. The group who had impending lower compared to...
2520 Background: PHA-739358 is a small molecule that inhibits AKs, serine/threonine family of proteins regulating mitosis. AKs are overexpressed in many tumor types. Methods: Objectives were to determine the MTD, cycle 1 dose-limiting toxicities (DLTs), safety, PK profiles and antitumor activity. Cohorts 3–6 pts allotted progressively higher dose levels (DL) based on number DLTs observed. defined as grade 4 neutropenia (G4 ANC) lasting >7 days, febrile (FN), neutropenic infection (NI), or...
BACKGROUND: Minimal invasive blood-based molecular markers are evaluated as promising biomarkers in malignant diseases these days. OBJECTIVE: In this pilot study, we investigated the potential of cell-free DNA (cfDNA) concentration and Integrity (cfDI) diagnostic marker s for ovarian cancer patients a retrospective study cohort. METHODS: cfDNA cfDI were determined plasma 37 28 healthy controls, by measuring ALU LINE1 repetitive elements using quantitative real-time PCR. RESULTS: A high...
Exosomes encompass a great deal of valuable biological information and play critical role in tumor development. However, the mechanism exosomal lncRNAs remains poorly elucidated bladder cancer (BCa). In this study, we identified lnc-TAF12-2:1 as novel biomarker BCa diagnosis aimed to investigate underlying function. Dual luciferase reporter assay, RNA immunoprecipitation (RIP), pulldown assays, xenograft mouse model were used verify competitive endogenous lnc-TAF12-2:1. We found up-regulated...
Abstract Two conformationally constrained tropane derivatives were prepared as rigid nicotinic acetylcholine receptor ligands. A palladium catalyzed intramolecular α‐arylation reaction was employed to generate the tricyclic compounds in good yields from N ‐(bromo‐chloropyridylmethyl)‐8‐azabicyclo[3.2.1]octan‐3‐ones.
We will present a case study of applying novel feature selection tool to breast cancer biomarker discovery. Using publicly available gene expression microarray dataset, we discovered prognostic biomarkers for various patient subpopulations stratified by clinical variables. then used independent datasets consist lymph node negative patients validate 20 potential The results show that our 20-gene signature as well many the discovery individual can achieve comparable or better performance...